Gyre Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Gyre Therapeutics, Inc. (NASDAQ: GYRE) is an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases. Headquartered in San Diego, California, the company operates primarily through its indirect controlling interest (69.7%) in Gyre Pharmaceuticals Co., Ltd., based in the People's Republic of China (PRC). Gyre's commercialized portfolio includes ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, alongside newly launched soft capsules Etorel (nintedanib ethanesulfonate) and Contiva. Its primary clinical asset is Hydronidone (F351), a structural derivative of pirfenidone being developed for chronic hepatitis B (CHB)-associated liver fibrosis in China and metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis in the United States.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical development of lead candidate Hydronidone (F351) into the United States, targeting MASH-associated liver fibrosis.
Expected impact: Establishes a clinical presence in the high-value U.S. market and addresses a significant unmet need in liver fibrosis.
Driving market penetration and sales growth of newly launched products in China, specifically Contiva (avatrombopag maleate, launched March 2025) and Etorel (nintedanib ethanesulfonate, launched June 2025), alongside the core product ETUARY.
Expected impact: Reduces concentration risk on ETUARY and establishes multiple revenue streams in the pulmonary and hepatic therapeutic areas.
Integrating Cullgen's proprietary ULF-PROTAC discovery engine and clinical-stage pipeline (including pan-TRK degrader CG001419) to build a robust pipeline of TPDs and degrader-antibody conjugates (DACs).
Expected impact: Positions Gyre as a fully integrated, multi-national biopharmaceutical company with advanced drug discovery capabilities spanning oncology, inflammatory diseases, and fibrosis.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Gyre's commercial operations and late-stage clinical pipeline in China with Cullgen's innovative targeted protein degradation (TPD) and degrader-antibody conjugate (DAC) platforms, creating a fully integrated U.S.- and China-based biopharmaceutical powerhouse.
Financial impact: Expands Gyre's pipeline with clinical-stage assets (CG001419 and CG009301) and adds a cost-efficient discovery engine in China, while increasing R&D commitments.
Strategic Partnerships
Acquired the commercial rights to nintedanib (marketed as Etorel) in China, allowing Gyre to offer both approved treatments for idiopathic pulmonary fibrosis (IPF) in the Chinese market.
Terms: Executed by subsidiary Gyre Pharmaceuticals in May 2024.